VISKEN
LOE ApproachingNDAORALTABLET
Approved
Sep 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VISKEN is an oral small-molecule tablet approved in 1982 by Novartis. The generic name and mechanism of action are not specified in available data. The product treats an undisclosed indication and is administered orally.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching; commercial teams should anticipate transition planning and potential downsizing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VISKEN has zero linked job openings and is approaching loss of exclusivity, making it a declining career opportunity. Professionals joining this product should expect transition-focused roles and limited growth potential.
Brand ManagerField Sales Representative
Worked on VISKEN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.